Fractyl Health, Inc. (NASDAQ:GUTS) Stock Now Rated “Hold” by Wall Street Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have been assigned an average recommendation of “Hold” from the five analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $50.25.

Several research firms have recently commented on GUTS. Morgan Stanley reduced their price target on Fractyl Health to $4.00 and set an “equal weight” rating on the stock in a report on Monday, October 19th. Wall Street Zen downgraded Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings cut Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Finally, Craig Hallum set a $5.00 target price on Fractyl Health in a research report on Monday, October 19th.

Institutional Investors Weigh In On Fractyl Health

A number of large investors have recently bought and sold shares of the stock. Nantahala Capital Management LLC bought a new stake in Fractyl Health during the second quarter valued at about $8,968,058. Bank of America Corp DE acquired a new position in shares of Fractyl Health in the second quarter valued at about $4,791,000. Pale Fire Capital SE raised its stake in shares of Fractyl Health by 84.5% in the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after acquiring an additional 2,711,103 shares in the last quarter. General Catalyst Group Management LLC acquired a new position in Fractyl Health in the 2nd quarter valued at $3,880,000. Finally, BlackRock Inc. bought a new position in Fractyl Health in the 2nd quarter worth about $1,431,000.

Fractyl Health Stock Performance

Shares of Fractyl Health stock opened at $0.93 on Friday. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 1.41. Fractyl Health has a 52 week low of $0.82 and a 52 week high of $29.34. The firm has a market capitalization of $12.33 million, a P/E ratio of -0.09 and a beta of 2.90. The firm’s 50 day moving average is $4.64 and its two-hundred day moving average is $7.47.

Fractyl Health (NASDAQ:GUTS) last posted its earnings results on Monday, August 10th. The company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.62) by $0.18. Research analysts forecast that Fractyl Health will post -5.88 EPS for the current fiscal year.

About Fractyl Health

Fractyl Health, Inc is a biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company aims to create treatments that address the underlying biology of these conditions and provide longer-lasting alternatives to frequently administered medicines.

Fractyl Health’s technology platforms include Revita, an endoscopic procedure designed to modify the lining of the duodenum and potentially improve metabolic function, and a gene therapy platform intended to enable the body to produce therapeutic levels of metabolic hormones such as glucagon-like peptide-1 (GLP-1).